Refocus Group's Mission is to Become a Surgical Standard of Care for Presbyopia, Primary Open-Angle Glaucoma and Ocular Hypertension Worldwide
Welcome to Refocus Group Inc., a medical device company engaged in the research and development of treatments for human vision disorders. Refocus Group owns over 90 domestic and international pending applications and issued patents, the vast majority directed to methods, devices, and systems for the treatment of presbyopia, ocular hypertension, and primary open angle glaucoma.
Please note that the company’s primary product, the PresView™ Scleral Implant, is an investigational device and is not yet approved for sale or use in the United States or Canada. However, the product is currently approved for sale in the European Union.
Ongoing Clinical Trials
Clinical Trails of Refocus Group's PresView™ Scleral Spacing Procedure are underway worldwide.
For more information on the current status of our ongoing clinical trails and studies in the United States and abroad please click on the "Clinical Investigation" menu tab at left.
If you are interested in participating as a clinical investigator for the Refocus Group's PresView™ Scleral Spacing Procedure, please contact Selene Burke at sburke@refocus-group.com.
|
 |
| PresView™ SSP and Presbyopia |
|
|
 |
| PresView™ SSP and Glaucoma |
|
|
|
